AIM movers: DBAY bids for Alliance...

AIM movers: DBAY bids for Alliance...

AIM movers: DBAY bids for Alliance...

Alliance Pharma (LON: APH) is recommending a bid of 62.5p/share by Aegros Bidco, which is owned by DBAY Affiliates and the ERES IV Fund. That values the healthcare brands owner at £349.7m. There is an alternative of one rollover share in the bid vehicle for each Alliance Pharma share. DBAY has been building up a … Read more

Health Check: On Lamington Day, biotechs...

Health Check: On Lamington Day, biotechs...

On National Lamington day, biotech investors are lamentin’ nothing. Pic: Getty Images Today’s news is all sweet on trial progress, revenue and cash Amplia to raise capital after runaway share performance Tryptamine starts binge eating ‘magic mushie’ trial Today is National Lamington Day and biotechs are serving up a solid sponge-like base of news encased … Read more

3 reasons why investors have largely...

3 reasons why investors have largely...

Investors over the past few weeks have countenanced a barrage of tariff threats as the Trump administration has ratcheted up the pressure on U.S. trade partners ahead of its Aug. 1 deal deadline.

Chinese firms are waging price wars....

Chinese firms are waging price wars....

A store in a shopping mall in Beijing on Aug. 7, 2024. Pedro Pardo | Afp | Getty Images Fierce price wars in China are hitting industries from cars to food deliveries to solar panels, squeezing profits and worsening the country’s deflationary slide. Though consumers may be lured by ultra-cheap deals, the trade-offs for them … Read more

2 growth stocks backed by this...

2 growth stocks backed by this...

Image source: Getty Images It’s probably fair to say that VT Holland Advisors Equity Fund isn’t immediately familiar to a lot of British investors. Given that the fund is very much on the small side (only £39.3m), perhaps that’s unsurprising. But VT Holland Advisors holds a handful of exciting growth stocks, and has delivered excellent … Read more

Leerink Partnrs Issues Negative Estimate for...

Leerink Partnrs Issues Negative Estimate for...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) – Equities research analysts at Leerink Partnrs dropped their Q2 2025 earnings per share estimates for shares of Sarepta Therapeutics in a research report issued on Wednesday, July 16th. Leerink Partnrs analyst J. Schwartz now anticipates that the biotechnology company will post earnings per share of $0.72 for … Read more

3 simple strategies that can help...

3 simple strategies that can help...

Image source: The Motley Fool Not everyone who invests in the stock market has bags of money. But they do mostly have one thing in common: they invest to try and build wealth. Each investor has their own approach to that goal. But some commonalities can apply too. Here are three simple approaches that can … Read more

With P/E ratios below 7, are...

With P/E ratios below 7, are...

Image source: Getty Images When searching for cheap FTSE shares, many investors lean on well-known valuation metrics such as the price-to-earnings (P/E) ratio or the price-to-book (P/B) ratio. These figures can offer a quick snapshot of how the market currently values a business relative to its profits or assets.  A low P/E might hint at … Read more